Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIn the UK, tirzepatide is a prescription-only medicine, which means a qualified prescriber must assess your suitability before any supply is legal. There is no route that skips clinical review. Tirzepatide is licensed here under the brand name Mounjaro, made by Eli Lilly, and a valid prescription follows a structured consultation covering your BMI, your health history and any medicines you already take. The decision belongs to the prescriber, not to a waiting list or a website checkout. Understanding what that process actually involves, and what it means for you, is the most useful thing to read before you start. You can explore what the treatment itself involves on our tirzepatide overview page.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Most people searching for a tirzepatide prescription already have a clear goal in mind: they want to lose a meaningful amount of weight, they've read the trial numbers, and they want to understand whether they qualify. That's the right starting point. Tirzepatide (Mounjaro) is licensed in the UK for adults whose BMI sits at 30 or above, or at 27 or above if they live with a condition linked to their weight. Common qualifying conditions include type 2 diabetes, raised blood pressure, high cholesterol and obstructive sleep apnoea. Lower BMI thresholds can apply for certain ethnic backgrounds under UK clinical guidance, and a prescriber will confirm whether that applies to you.
What the licence doesn't do is guarantee that tirzepatide is the right fit for every person who technically qualifies. Your prescriber will also consider your medical history, your current medicines and whether there are any contraindications. People with a personal or family history of medullary thyroid carcinoma or MEN2, or those with a history of pancreatitis, will need a careful conversation before a prescription is appropriate. The same applies if you are pregnant, breastfeeding or trying to conceive: tirzepatide is not recommended during any of these. That assessment, carried out properly, is what makes the prescription legitimate. You can read more about the distinction between Mounjaro and tirzepatide if the two names have caused any confusion.
A prescriber who reviews your answers thoroughly before issuing a prescription is not making the process harder. They're making it safe.
A private tirzepatide prescription in the UK follows a clear sequence, and knowing each step takes the anxiety out of it. You complete a clinical consultation, either online or in person, covering your weight, your BMI, your health conditions and your current medicines. At a regulated online pharmacy, you'd also expect photo ID verification and live weight verification before anything is approved.
At nume, a GPhC-registered Independent Prescriber reads every consultation personally. Not software, not a triage algorithm: a named clinician. If the prescription is appropriate, it's issued the same day. Treatment dispatched before midday on a working day arrives the following working day via DPD, tracked, in plain packaging. The clinical team at nume's lead prescriber profile gives you a sense of who is doing that reviewing. For ongoing supply, every repeat order goes through a fresh clinical review rather than an automatic renewal, which means dose increases are evidence-based, not just scheduled.
One practical note on timing: if you're planning to start around a bank holiday or just before a holiday yourself, it's worth factoring in that same-day dispatch requires a working-day order before midday. Our FAQs cover dispatch and delivery questions in detail.
To verify that any online pharmacy dispensing tirzepatide holds GPhC registration, you can check the GPhC pharmacy register directly.
Tirzepatide is not available on the NHS for most people right now. The NHS rollout is phased and the eligibility criteria are strict, so the majority of people taking it privately pay out of pocket. That makes cost a real factor in the decision, and it deserves a straight answer.
Private tirzepatide treatment is priced per pen, per month, and prices have shifted since Eli Lilly raised the UK list price for Mounjaro in September 2025. Reported private-market prices now range roughly £149–£375 per month depending on dose and provider, and if you want to understand how costs change as you step up through the programme, our pages covering tirzepatide 10 mg and tirzepatide 30 mg set out what to expect at those respective doses. Our Mounjaro pricing page gives honest context on what's typical and what a single transparent price should cover.
The thing worth knowing is that the prescription fee, the consultation, the delivery and any aftercare support are sometimes priced separately by different providers. A headline figure that looks lower can add up to more once those extras appear. For a prescription medicine, the question isn't just what you pay at checkout; it's whether the clinical review behind it is thorough, whether the supply chain is licensed and whether you'll have support if a question comes up at 9pm on a Sunday. Those factors don't show up in a price comparison table, but they matter considerably more than a saving of a few pounds per pen.
A tirzepatide prescription is the beginning of a clinical relationship, not a one-time transaction. Treatment starts at 2.5 mg weekly. The first month's job is settling your system: the starter dose is chosen for tolerability, and most people's side effects are at their most noticeable during the early weeks. Nausea, some digestive discomfort and occasional fatigue are common, particularly when the dose steps up. These generally ease within days to a couple of weeks as your body adjusts, as described on the NHS tirzepatide medicines page.
Dose increases are managed by the prescriber and should be supported by clinical review rather than happening automatically. Women using the oral contraceptive pill need to know that tirzepatide can reduce how well the pill is absorbed, particularly in the first four weeks of treatment and for four weeks after each dose increase. Adding a non-oral method of contraception during those windows is the standard recommendation from NHS guidance. People taking HRT may also want to discuss transdermal formats with their doctor for the same reason.
If you're already on treatment elsewhere and want to transfer, a reputable prescriber will ask for evidence of your current dose before continuing at that level, and our tirzepatide L pen guide is useful reading if you have questions about a specific pen format you've been using. That evidence requirement protects you. Details on the full treatment landscape, including how Mounjaro fits within the broader weight-loss treatment options, are available if you want to read wider before deciding.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.